CSF2 and neutropenia: While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia.